Rituximab

Association of B-cell subsets and AQP4 antibody titers with disease activity in NMOSD 2:51
Association of B-cell subsets and AQP4 antibody titers with disease activity in NMOSD
Friedemann Paul • 27 Apr 2023
GFAP and NfL as biomarkers in NMOSD 3:31
GFAP and NfL as biomarkers in NMOSD
Celia Oreja-Guevara • 24 Mar 2023
Long-term treatment with anti-CD20 mAbs – is it feasible? 2:50
Long-term treatment with anti-CD20 mAbs – is it feasible?
Emma Tallantyre • 23 Sep 2022
Diagnostic work up of autoimmune neurological conditions 3:13
Diagnostic work up of autoimmune neurological conditions
Divyanshu Dubey • 12 Apr 2022
Deep learning can predict treatment response in patients with progressive MS 8:42
Deep learning can predict treatment response in patients with progressive MS
Jean-Pierre Falet • 22 Mar 2022
Efficacy of inebilizumab in patients with NMOSD with Fc receptor III-A polymorphisms 5:12
Efficacy of inebilizumab in patients with NMOSD with Fc receptor III-A polymorphisms
Bruce Cree • 13 Jun 2022
Key considerations for clinicians treating NMOSD 2:27
Key considerations for clinicians treating NMOSD
Bruce Cree • 13 Jun 2022
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs 3:15
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs
Virginia Meca-Lallana • 28 Feb 2022
COVID booster vaccines do not lead to humoral responses in patients with MS treated with DMTs 1:57
COVID booster vaccines do not lead to humoral responses in patients with MS treated with DMTs
Celia Oreja-Guevara • 24 Feb 2022
The importance of assessing autoreactive T-cell responses in MS 2:25
The importance of assessing autoreactive T-cell responses in MS
Olivia Thomas • 21 Oct 2021
Comparing exit strategies in natalizumab-responders at high risk for PML 7:33
Comparing exit strategies in natalizumab-responders at high risk for PML
Emanuele D'Amico • 30 Sep 2021
COVID-19 vaccination in patients with MS 7:22
COVID-19 vaccination in patients with MS
Maria Pia Sormani • 13 Oct 2021
COVID-19 cases in MS patients receiving IV therapy 1:49
COVID-19 cases in MS patients receiving IV therapy
Celia Oreja-Guevara • 14 Oct 2021
How does ublituximab compare to other anti-CD20 mAbs? 1:14
How does ublituximab compare to other anti-CD20 mAbs?
Lawrence Steinman • 15 Oct 2021
Humoral response to COVID-19 vaccination in patients with MS 6:28
Humoral response to COVID-19 vaccination in patients with MS
Celia Oreja-Guevara • 14 Oct 2021
Real-world comparison of natalizumab exit strategies in patients with RRMS 9:25
Real-world comparison of natalizumab exit strategies in patients with RRMS
Aurora Zanghì • 22 Jun 2021
The content of VJNeurology is intended for healthcare professionals